<DOC>
	<DOCNO>NCT02795416</DOCNO>
	<brief_summary>Secukinumab target different interleukin potential use alternative exist treatment . This study provide clinical data respect efficacy Psoriasis Area Severity Index ( PASI ) 16 week , safety/tolerability secukinumab evaluate impact treatment quality life work productivity subject moderate severe plaque psoriasis Turkish population .</brief_summary>
	<brief_title>Assessment Efficacy Safety Secukinumab Adult Patients Turkish Population</brief_title>
	<detailed_description>To demonstrate efficacy secukinumab subject moderate severe plaque psoriasis base percentage PASI 90 responder patient Week 16 compare baseline Evaluation onset efficacy measure percentage patient achieve PASI 75 PASI 90 week 4 The efficacy treatment use Investigator 's Global Assessment modify 2011 ( IGA mod 2011 ) week 4 week 16 Work productivity ( measure WPAI-PSO ) Week 16 Changes quality life measure Dermatology Life Quality Index ( DLQI ) Week 16 Health assessment questionnaire -Disability index ( HAQ-DI ) patient psoriatic arthritis ( PsA )</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects must able understand comply requirement study communicate investigator Diagnosis chronic plaque psoriasis least 6 month enrollment Patients evaluate candidate systemic therapy , define psoriasis intolerant /and inadequately control : topical treatment ( include topical corticosteroid ) and/or phototherapy and/or previous systemic treatment psoriasis previous treatment biologic agent Forms psoriasis plaque psoriasis Druginduced psoriasis Previous exposure secukinumab biologic drug directly target IL17A IL17RA Pregnant nursing ( lactate ) woman Active ongoing inflammatory disease psoriasis psoriatic arthritis might confound evaluation benefit secukinumab Underlying condition ( include , limited metabolic , hematologic , renal , hepatic , pulmonary , neurologic , endocrine , cardiac , infectious gastrointestinal condition ) Preexisting recentonset central peripheral nervous system demyelinate disorder Significant medical problem , include limited following : uncontrolled hypertension , congestive heart failure Active systemic infection 2 week prior enrollment History ongoing , chronic recurrent infectious disease , evidence tuberculosis infection Past medical history record , current infection , human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C prior enrollment History lymphoproliferative disease know malignancy history malignancy organ system within past 5 year History evidence ongoing alcohol drug abuse , within last 6 month prior enrollment Plans administration live vaccine study period 6 week prior enrollment Not willing limit UV light exposure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Moderate severe plaque psoriasis , PASI , secukinumab , monoclonal antibody , Turkish population</keyword>
</DOC>